Catalyst Wire Dossier Catalyst Wire Dossier

lifitegrast ophthalmic solution 5.0%

lifitegrast
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for lifitegrast ophthalmic solution 5.0%, covering 2018-10-25 to 2018-10-25. Get the full timeline:

Most recent: Clinical Trial Update: Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers [Phase 4]

See pricing